SABS

SAB Biotherapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/08/26

Business Summary

SAB Biotherapeutics operates in biotechnology, developing therapeutic candidates derived from advanced biological platforms aimed at addressing infectious and immune-related diseases. The company’s model centers on leveraging proprietary biologic development capabilities to create differentiated antibody-based treatments. Cash generation, when achieved, comes from advancing candidates through clinical milestones, securing partnerships, and eventual commercialization or licensing agreements. Its moat depends less on scale and more on intellectual property, scientific know-how, and regulatory progress that create barriers to replication and extend the economic life of its therapeutic assets.

 


Analyze SABS on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$263

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

1.7

EV / EBITDA

10.4

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$0.22

Next Year EPS Growth Estimate

-$0.33

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

8.80%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

4

Altman Z-Score

6.2

Return on Invested Capital (ROIC)

12.90%

Current Ratio

9.5

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze SABS on TradingView

Gainseekers Quantitative Analysis

Summary

At a $263M market cap with a Price/Book of 1.7, ROIC of 12.90%, and an Altman Z-Score of 6.2, this balance sheet screens far stronger than the typical small-cap biotech. The absence of a Forward P/E and PEG ratio removes conventional growth valuation anchors, but the Z-Score of 6.2 and a Current Ratio of 9.5 signal exceptional financial stability and low near-term insolvency risk. EPS is reported at 10.4 while next year’s estimate drops to $0.22 and Sales Growth Next Year is -$0.33, indicating normalization or volatility in earnings power. The market is not clearly pricing aggressive growth, and without leverage pressure (Debt/Equity not listed) the story is more about durability than acceleration. This is not a momentum biotech; it is a balance-sheet-secured speculative asset with asymmetric optionality rather than a clean GARP compounder.

AI Exposure / Tech Reliance

Biotechnology is inherently data-driven, and AI integration in drug discovery, antibody engineering, and clinical trial optimization is becoming table stakes. As a Healthcare company in Biotechnology, SABS operates in a segment that increasingly depends on computational biology and AI-enhanced modeling to compress R&D timelines. Its ability to remain competitive will hinge on leveraging advanced analytics to increase capital efficiency rather than expanding physical infrastructure.

The Bull Case

A value-oriented or GARP investor could justify ownership purely on capital efficiency and financial resilience. A 12.90% ROIC in biotech is not trivial, particularly when paired with an 8.80% Operating Margin and a Price/Book of 1.7, which suggests the market is not overpaying for its asset base. The Piotroski F-Score of 4 is neutral, not distressed, and combined with an Altman Z-Score of 6.2 and a Current Ratio of 9.5, the balance sheet looks fortress-like relative to its $263M size. There is no dividend drain (TTM Yield 0, Dividend 5-Year Avg 0), so capital is being retained internally. If management can stabilize earnings closer to the $0.22 forward EPS trajectory while sustaining double-digit ROIC, the current valuation could represent a deep value entry with limited bankruptcy risk.

The Bear Case

The red flags are embedded in the growth profile and visibility. Forward P/E and PEG Forward are absent, removing any clarity on earnings-based valuation relative to growth, and Sales Growth Next Year is -$0.33, signaling contraction rather than expansion. EPS collapses from 10.4 to an estimated $0.22 next year, a dramatic normalization that questions earnings durability. Institutional Ownership at 9.89% is low, suggesting limited smart-money conviction, and the Mean Consensus Target Price of 1.4 implies muted upside expectations. With no listed Debt/Equity, Return on Equity, or Short % of Float data, transparency gaps themselves become a structural risk for serious capital allocators.

Market Sentiment & Smart Money

Short Interest %

4.10%

Analyst Consensus

1.4

Average Analyst Price Target

$9.89

Institutional Ownership %

58.80%

1-Year Beta

0.77

Insider Buying % (6 Mo)

1.00%%

Distance to 52-Week High

56.80%

Distance to 52-Week Low

326.10%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.